Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 7009–7015 | Cite as

Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?

  • Roberto Angioli
  • Stella Capriglione
  • Alessia Aloisi
  • Federica Guzzo
  • Daniela Luvero
  • Andrea Miranda
  • Patrizio Damiani
  • Roberto Montera
  • Corrado Terranova
  • Francesco Plotti
Research Article

Abstract

Actually, in literature there are not valid tools able to predict the chemotherapy response during first-line ovarian cancer treatment. CA125 and human epididymis protein 4 (HE4) levels of consecutive single-institution patients with epithelial ovarian cancer (EOC) were measured during first-line chemotherapy and until 6 months follow-up. First, patients were divided into two groups according to a temporal criterion: patients treated during 2009 (group A: training group) and patients treated during 2010 (group B: verification group). At sixth months follow-up, patients were sub-classified, within both groups, as platinum resistant or platinum sensitive/intermediate, according to Response Evaluation Criteria in Solid Tumors criteria, and the serum marker courses were further analyzed in each subgroup. Moreover, we performed a logistic regression analysis to choose CA125 and HE4 levels that are best fitted to predict chemoresponse. A total of 76 patients were divided into two groups: group A (n = 42) and group B (n = 34). After 6 months of follow-up, 40 patients were classified as platinum sensitive/intermediate and 36 as platinum resistant. At third chemotherapy cycle, in platinum-resistant patients, HE4 levels were >70 pmol/L in 36 of 36 cases, although in platinum-sensitive/intermediate patients, HE4 levels were >70 pmol/L only in six of 40 cases (sensitivity 100 %, specificity 85 %). Moreover, HE4 reduction of almost 47 % at third chemotherapy cycle reached the sensitivity of 83 % with a specificity of 87 % (positive predictive value = 0.86, negative predictive value = 0.85) in predicting chemoresponse. On the contrary, CA125 values during chemotherapy did not result statistically significant in predicting platinum response. Our findings suggest that HE4 values during first-line chemotherapy could predict chemotherapy response in EOC patients.

Keywords

Ovarian cancer HE4 CA125 Chemoresponse Platinum sensitive Platinum resistant 

Notes

Conflicts of interest

None

References

  1. 1.
    Berek JS, Crum C. Friedlander M Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119 Suppl 2:S118–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 2003;17:957–68.CrossRefPubMedGoogle Scholar
  3. 3.
    Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol. 1989;7:1667–71.PubMedGoogle Scholar
  7. 7.
    Koper NP, Massuger LFAG, Thomas CMG, Kiemeney LALM, Schijf CPT, Beex LVAM, et al. Prognostic value of serial CA 125 measurements during chemotherapy for patients with advanced ovarian cancer. Int J Gynecol Cancer. 1997;7:127–33.CrossRefGoogle Scholar
  8. 8.
    Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992;44:207–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Latimer JA, Beng CG, Davy MLJ. For stage III epithelial ovarian cancer the initial level of expression of CA 125 does not correlate with survival in women who respond to treatment. Int J Gynecol Cancer. 1996;6:380–4.CrossRefGoogle Scholar
  10. 10.
    Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999;81:662–6.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, et al. A risk model for ovarian carcinoma patients using CA 125. Cancer. 1996;77:1122–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Rocconi RP, Matthews KS, Kemper MK, et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;114:242–5.CrossRefPubMedGoogle Scholar
  13. 13.
    World Health Organization. WHO handbook for reporting results of cancer treatment (offset publication no. 48). Geneva: World Health Organization; 1979. p. 16–21.Google Scholar
  14. 14.
    van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HWA, Dobler-Girdziunaiti D, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000;79:444–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33(6):2117–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  18. 18.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMedGoogle Scholar
  19. 19.
    Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer. 2011;21(6):1040–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Roberto Angioli
    • 1
  • Stella Capriglione
    • 1
  • Alessia Aloisi
    • 1
  • Federica Guzzo
    • 1
  • Daniela Luvero
    • 1
  • Andrea Miranda
    • 1
  • Patrizio Damiani
    • 1
  • Roberto Montera
    • 1
  • Corrado Terranova
    • 1
  • Francesco Plotti
    • 1
  1. 1.Department of Obstetrics and GynaecologyUniversity of Rome “Campus Bio-Medico”RomeItaly

Personalised recommendations